uk recell trial, page-7

Andrew Cannon (CCE's CFO) says the following:


There is no underlying reason behind the share
price movement other than general market weakness and tax loss selling
may well be having an impact. CellSpray continues to be used in Europe
(we are focusing on Germany) with good outcomes and hospitals are
reordering the product which indicates they are happy with the outcomes.
As we have stated we will be concentrating on key approved markets to
generate the sales forecasts we announced in March.

Kind regards

Andrew


Andrew Cannon Chief Financial Officer
Clinical Cell Culture
13 - 15 Hills Road, Cambridge CB2 1NL